Early discovery programs for PROTACs and RIPTACs often face pressure to move quickly while generating the chemistry and biology data needed to support compound selection and program progression. This ...

Scientists created a definitive E3 ligase atlas, resolving inconsistencies and enabling better disease research and drug ...

CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune responses. In cancer, however, this ...

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic ...

Cells rely on tiny molecules called microRNAs to tune which genes are active and when. Cells must carefully control the ...

The fireside chat will be webcast live and may be viewed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event.

Cell function is significantly influenced by a process called ubiquitination, in which molecules are selected for elimination ...

SEED Therapeutics, Inc. ("SEED"), a clinical-stage biotechnology company specializing in molecular glue degraders, today announced that it will have a poster presentation at the 2026 Annual Meeting of ...

WEHI researchers have led a major global effort to create the first authoritative atlas for a class of enzymes that regulate almost every cellular process in the human body. Published in Cell, the ...

IKZF1-4 are transcription factors that regulate cellular differentiation, proliferation and survival. At the American Chemical Society (ACS) Spring 2026 meeting this week in Atlanta, Bristol Myers ...

FDA fast track designation applies to ALK+ NSCLC progressing after ≥2 ALK TKIs, reflecting limited post-lorlatinib therapeutic options and enabling more frequent FDA interactions and potential rolling ...

Detailed price information for Nurix Therapeutics Inc (NRIX-Q) from The Globe and Mail including charting and trades.